RTW Investments LP

07/14/2026 | Press release | Distributed by Public on 07/15/2026 07:38

Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.
RTW Investments LP published this content on July 14, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on July 15, 2026 at 13:38 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]